Combined therapy with inhaled nitric oxide and intravenous prostacyclin in an infant with alveolar-capillary dysplasia

Am J Respir Crit Care Med. 1997 Feb;155(2):743-6. doi: 10.1164/ajrccm.155.2.9032222.

Abstract

Severe persistent pulmonary hypertension of the newborn (PPHN) remains a significant cause of neonatal morbidity and mortality with limited effective treatment options. We present the first case of a neonate with PPHN treated concurrently with inhaled nitric oxide (iNO) and intravenous prostacyclin (PGI2). He ultimately was diagnosed with alveolar-capillary dysplasia, a rare and fatal cause of pulmonary hypertension. However, his partial response to treatment demonstrates a possible role for combined therapy with iNO and PGI2 in infants with severe PPHN.

Publication types

  • Case Reports

MeSH terms

  • Antihypertensive Agents / therapeutic use*
  • Echocardiography
  • Epoprostenol / administration & dosage*
  • Fatal Outcome
  • Humans
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / etiology
  • Hypertension, Pulmonary / physiopathology
  • Infant, Newborn
  • Infant, Newborn, Diseases / drug therapy*
  • Infant, Newborn, Diseases / physiopathology
  • Male
  • Nitric Oxide / administration & dosage*
  • Pulmonary Artery / abnormalities
  • Pulmonary Veins / abnormalities

Substances

  • Antihypertensive Agents
  • Nitric Oxide
  • Epoprostenol